

THE EXPERIENCE OF ADMINISTRATION OF DOMESTIC 4TH GENERATION FLUOROQUINOLONE BIGAFLON® IN TREATMENT OF SEVERE RESPIRATORY INFECTIONS

A. S. Svintsytskiy, A. I. Taran, A. V. Volkova

Summary

In order to study the efficacy and safety of preparation Bigaflon®, 0,4 % solution for infusions in 100 ml vials, produced by "Yuriya-Pharm" Ltd., there was conducted an open-label comparative parallel group trial of Bigaflon® vs Tebris, 0,2 % solution for infusions in 200 ml vials, produced by "Mili Healthcare" (Great Britain), in treatment of exacerbations of chronic bronchitis. Bigaflon® caused significant anti-inflammatory and anti-bacterial effect during the chronic bronchitis exacerbation. It was effective in 93 % of patients. All antibacterial effect parameters (susceptible pathogens, decrease and normalization of body temperature, sputum pattern, blood count normalization) of Bigaflon® were about the same as in reference drug Tebris.